Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Recombinant trivalent rotavirus subunit vaccine (Escherichia coli) clinical trial application has been accepted.

Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly-owned subsidiary Xiamen Wantai Canghai Biological Technology Co., Ltd. has received the administrative license document "Acceptance Notification" from the National Medical Products Administration. The company's application for clinical trials of the recombinant trivalent rotavirus subunit vaccine (E. coli) has been accepted. The acceptance of the application for clinical trials of the recombinant trivalent rotavirus subunit vaccine (E. coli) is an important step in the company's innovative vaccine research and development process. It signifies a key progress in the company's development strategy for recombinant protein vaccines based on its independent E. coli technology platform. If this product is successfully marketed in the future, it will enrich the company's product portfolio and further enhance its market competitiveness.